Drug · Monoclonal Antibody

Ramucirumab

CI-DRUG-00000507Explore in graph →NCIt C70792 CHEMBL1743062 CIViC Approved

Regulatory

Approvals (14)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CYRAMZA (DIN 02443805) under ATC L01FG02 RAMUCIRUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 10, 2015	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 14 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	37	16	21	135	14	CA, EU, US	Apr 21, 2014	2005-01
Malignant Lung Neoplasm	Approved	Phase 3	18	7	6	37	2	US	Apr 21, 2014	2009-01
Malignant Liver Neoplasm	Approved	Phase 3	0	0	1	7	1	US	Apr 21, 2014	2008-02
Malignant Gastric Neoplasm	Phase3	Phase 3	13	6	8	37	0

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 R678Q1
Ramucirumab	Gastric Adenocarcinoma

Clinical trials

Trials with this intervention (137)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 137 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03560973	A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM(RAMES)	completed	Phase 2	164	Gruppo Oncologico Italiano di Ricerca ClinicaOTHER	1	Mar 13, 2025	clinicaltrials
NCT02795858	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Vascular endothelial growth factor receptor 2 inhibitor
Targets: 1 gene
UNII: D99YVK4L0X
Aliases: 1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, CYRAMZA, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY3009806, Monoclonal Antibody HGS-ETR2, Ramucirumab

Data updated 17 hours agoSource updated unknown

Identifiers

Codes (5)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FG02	RAMUCIRUMAB
ATC (WHO)	L01FX06	Antineoplastic agents
DIN (Health Canada)